Citius (CTXR). Dang Flippers!
Short term investors powered Citius from $2.50 to near $4.50 in hopes of a positive early trial...
Teplizumab: Can We Delay the Onset of Type 1? (DiaTribe)
Teplizumab: Can We Delay the Onset of Type 1?
Last updated: 6/7/21
By Dr. Francine...
Citius (CTXR) Expands Scientific Advisory Board. Dr. John Laffey, Expert in Stem Cell and...
- Addition of leading scholar and KOL in acute respiratory distress syndrome (ARDS) to ARDS Scientific Advisory Board supports continued progress of...
More Great News From Citius Pharma (CTXR).
UPDATED CHART 6-15-21
Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News
Stocks On The Move!
Citius (CTXR) up 19%, Draganfly (DFLYF) up 31%, urban-gro (UGRO) up 37%, Provention (PVRB) flip-flopping, Hapbee Technologies (HAPBF) up 26% and the...
Provention Bio (PRVB) Updates.
LATEST UPDATE July 13th, 2022, below.
(2021) We're getting way too many calls on...
Adding Hapbee Tech (HAPB, HAPBF) $0.34 to Biotech Six Pack Watch List.
UPDATE ON BIOTECH SIX PACK, SIX STOCKS WE EXPECT TO DOUBLE.
While the Biotech Stock Review was launched...
Citius Pharma (CTXR) Updates Shareholders.
Citius Update Stem Cell Study
Citius Pharmaceuticals, Inc announced that it will present a poster at the International Society...
Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.
https://youtu.be/vMIy8xWLOKI?t=3699
Starts at 1 Hour Mark.
INSIDER HOLDINGS
Interview: Scott Donnell from Hapbee (HAPB, HAPBF) on Wall Street Reporter.
Transcript follows.
Hapbee CEO Live with the Wall Street Reporter
Listen in as Hapbee CEO...
Latest article
Adding Quantum Pharmaceutical (QNTM) $4.10 to Reverse Split Stock Watch List.
119% Gain Post Split
Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
(March 2024) When we finished writing our earlier...
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value...
